Active substance finerenone
Holder Bayer
Status Running
Indication Adult patients with chronic kidney disease (CKD) (stage 3 & 4 with albuminuria) associated with type 2 diabetes (T2D) who cannot be satisfactorily treated with the standard of care.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 27/09/2022


Last updated on 28/09/2022